flavin-mononucleotide has been researched along with Osteosarcoma* in 1 studies
1 other study(ies) available for flavin-mononucleotide and Osteosarcoma
| Article | Year |
|---|---|
Cytotoxicity of Nucleotide-Stabilized Graphene Dispersions on Osteosarcoma and Healthy Cells: On the Way to Safe Theranostics Agents.
An appealing strategy that overcomes the hydrophobicity of pristine graphene and favors its interaction with biological media is colloidal stabilization in aqueous medium with the support of a biomolecule, such as flavin mononucleotide (FMN), as exfoliating/dispersing agent. However, to establish FMN-stabilized graphene (PG-FMN) as suitable for use in biomedicine, its biocompatibility must be proved by a complete assessment of cytotoxicity at the cellular level. Furthermore, if PG-FMN is to be proposed as a theranostic agent, such a study should include both healthy and tumoral cells and its outcome should reveal the nanomaterial as selectively toxic to the latter. Here, we provide an in-depth comparative in vitro analysis of the response of Saos-2 human sarcoma osteoblasts (model tumor cells) and MC3T3-E1 murine preosteoblasts (undifferentiated healthy cells) upon incubation with different concentrations (10-50 μg mL Topics: 3T3 Cells; Animals; Antineoplastic Agents; Biocompatible Materials; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Flavin Mononucleotide; Graphite; Humans; Materials Testing; Mice; Osteosarcoma; Particle Size; Theranostic Nanomedicine | 2021 |